Gene Therapy to Treat Cancer for First Time
By Press Trust of India,
Press Trust of India
| 06. 19. 2008
In the first case of its kind, doctors have treated a cancer patient by injecting him with billions of his own immune cells, a development that projects the huge power of gene therapy for the killer disease.
According to reports in the New England Journal of Medicine, US researchers treated a 52-year-old man of melanoma by cloning cells from the patients own defence system and injecting them back into his body, in a process known as "immunotherapy".
The man was free from tumours within eight weeks of undergoing the procedure. After two years he is still free from the disease which had spread to his lymph nodes and one of his lungs. "For this patient we were successful, but we would need to confirm the effectiveness of therapy in a larger study," Dr Cassian Yee, who led the team at the Fred Hutchinson Cancer Research Centre in Seattle.
The treatment, which is extremely expensive at this stage of development, showed that vast numbers of immune cells in the body can be safely and effectively used to treat skin cancer, The...
Related Articles
By Rob Stein, NPR [cites CGS' Katie Hasson] | 08.06.2025
A Chinese scientist horrified the world in 2018 when he revealed he had secretly engineered the birth of the world's first gene-edited babies.
His work was reviled as reckless and unethical because, among other reasons, gene-editing was so new...
By Kristel Tjandra, Genetic Engineering & Biotechnology News | 07.30.2025
CRISPR has taken the bioengineering world by storm since its first introduction. From treating sickle cell diseases to creating disease-resistant crops, the technology continues to boast success on various fronts. But getting CRISPR experiments right in the lab isn’t simple...
By Arthur Caplan and James Tabery, Scientific American | 07.28.2025
An understandable ethics outcry greeted the June announcement of a software platform that offers aspiring parents “genetic optimization” of their embryos. Touted by Nucleus Genomics’ CEO Kian Sadeghi, the $5,999 service, dubbed “Nucleus Embryo,” promised optimization of...
By Keith Casebonne and Jodi Beckstine [with CGS' Katie Hasson], Disability Deep Dive | 07.24.2025
In this episode of Disability Deep Dive, hosts Keith and Jodi explore the complex interplay between disability science, technology, and ethics with guest Katie Hasson, Associate Director at the Center for Genetics and Society. The conversation delves into...